Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review

Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review

BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, is highly prone to recurrence, and has a short survival period. It is very difficult to achieve long-term survival in ES-SCLC, which has not been significantly improved in the last 20 years. For a long time, platinum-bas...

Full description

Bibliographic Details
Main Authors: Xu Zhang, Jiabin Zheng, Yun Niu, Chongxiang Xue, Yixuan Yu, Kexin Tan, Huijuan Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
ES-SCLC
long-term survival
ICIs
re-challenge
combined regimens
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1059331/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1059331/full

Similar Items